07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Crystal structure of myeloid leukemia cell differentiation protein (MCL1)

Drug platforms TECHNOLOGY: Crystal structures Crystallographic studies on an MCL1 fusion protein could aid the structure-based design of MCL1-specific inhibitors. A fusion of maltose binding protein and MCL1 containing three mutations to enhance its crystal...
07:00 , Jun 18, 2015 |  BC Innovations  |  Translation in Brief

Watershed crystal

Beryllium LLC and The Broad Institute of MIT and Harvard have found a way to crystallize myeloid leukemia cell differentiation protein (MCL1) that can be used for both its free and ligand-bound forms. The partners...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

ArQule, Beryllium deal

ArQule and Beryllium will identify and develop small molecule compounds against PD-1 and PD-L1 using Beryllium’s drug discovery platforms. The companies will bear their own costs during preclinical testing, jointly decide which compounds to further...
07:00 , May 26, 2014 |  BC Week In Review  |  Financial News

Beryllium completes venture financing

Beryllium LLC , Bedford, Mass.   Business: Supply/Service   Date completed: 5/20/14   Type: Venture financing   Raised: Not disclosed   Investor: UCB Group  ...
08:00 , Dec 7, 2009 |  BioCentury  |  Strategy

Two Genomic Sagas

Despite being in the vanguard of the genomics revolution, deCode Genetics Inc. struggled to take up the drug development mantle as others have done. Now, having raised just over $1.1 billion from the sale of...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

deCode cardiovascular, diagnostic, genomics news

deCode filed for Chapter 11 bankruptcy to facilitate the sale of its assets. The company plans to sell its Islensk Erfdagreining subsidiary to Saga Investments LLC. Islensk conducts deCode's human genetics research, manages its population...
02:11 , Nov 18, 2009 |  BC Extra  |  Company News

deCode files for Chapter 11

deCode genetics Inc . (NASDAQ:DCGN) filed for Chapter 11 bankruptcy to facilitate the sale of its assets. The company plans to sell its Islensk Erfdagreining subsidiary to Saga Investments LLC. Islensk conducts deCode's human genetics...